Since the Kefauver-Harris amendments of 1962, the US Food and Drug Administration (FDA) has required evidence of efficacy to approve a drug for marketing in the United States. For many years, information about benefits and risks was assembled at the time of approval, and if the benefits appeared to exceed the risks known at the time, the drug was deemed safe for approval. In practice, a drug that demonstrated efficacy according to the prespecified outcomes in the phase 3 trials was approved for marketing unless there was convincing evidence of a serious risk.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.